Scancell (SCLP.PL), the developer of therapeutic cancer and infectious disease vaccines based on its
patented ImmunoBody® platform, is pleased to announce the interim results for the six month period ended 31st October 2009 (‘the period’).
Highlights:
- Licensing agreement signed with Merck KGaA for two key patents required for further development and commercialisation of protein ImmunoBody® vaccines
- Agreement signed with Ichor Medical Systems to use Ichor's TriGrid™ electroporation device for the delivery of SCIB1
- Signed a research agreement with ImmunoVaccine Technologies Inc. to explore IVT’s DepoVax™ delivery system for future use with Scancell’s ImmunoBody® DNA infectious disease and animal health vaccines
Post Period Highlights:
- GMP production of SCIB1 vaccine completed successfully with excellent yield
- PharmaNet Development Group appointed to conduct and manage the SCIB1 clinical trial
David Evans, Non-Executive Chairman of Scancell, commented:
“The Company is on track with its clinical programme as outlined in our admission document in 2008, and we look forward to further progress during the current year, as SCIB1 enters Phase I clinical trials.”
A copy of this announcement is available for download at Announcement
The interim financial information is not audited.
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc - +44 (0)207 245 1100
Kirsty Corcoran/John Bick - Hansard Communications - +44 (0)207 245 1100/+44 (0)7515 588 947
Ross Andrews - Zeus Capital - +44 (0)161 831 1512
View the full results